| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
Fosfosal's mechanism of action is not fully understood. As a salicylic acid derivative, it is thought to exert its anti-inflammatory and analgesic effects through inhibition of cyclooxygenase (COX) enzymes, though it does not affect prostaglandin biosynthesis in vitro. It may act through other pathways, such as the modulation of NF-κB or other inflammatory mediators.
|
|---|---|
| ln Vitro |
In vitro, fosfosal has analgesic and anti-inflammatory activity. It does not affect prostaglandin biosynthesis in vitro, suggesting a mechanism distinct from that of traditional NSAIDs. It is used as a substrate for the estimation of acid phosphatase.
|
| ln Vivo |
In vivo, fosfosal is used as an analgesic and anti-inflammatory drug. It has been used for many years in medical research. Its efficacy in reducing pain and inflammation has been demonstrated in clinical use, although its mechanism is not fully understood.
|
| Enzyme Assay |
In vitro enzyme assays for fosfosal involve measuring its inhibition of acid phosphatase activity. The compound is used as a substrate for the estimation of acid phosphatase. Its effects on COX enzymes can also be assessed, although it does not affect prostaglandin biosynthesis.
|
| Cell Assay |
In vitro cell-based assays for fosfosal are not typically performed. Its activity is characterized by its analgesic and anti-inflammatory effects in animal models. Its effects on inflammatory mediators can be assessed in cell culture.
|
| Animal Protocol |
In vivo animal experiments for fosfosal have been conducted in models of pain and inflammation. The compound is typically administered orally. Efficacy is measured by reduction in pain responses and inflammatory markers.
|
| ADME/Pharmacokinetics |
Fosfosal has a molecular weight of 218.10 and a molecular formula of C7H7O6P. It has a melting point of 169°C. It is a white or off-white crystalline powder. It is soluble in DMSO (37 mg/mL). Its purity is ≥97%.
|
| Toxicity/Toxicokinetics |
Fosfosal is a drug with a known safety profile. As an NSAID, it may have gastrointestinal side effects. It is generally well-tolerated. It is a research compound and is not intended for human use without proper authorization. Standard safety precautions should be taken when handling.
|
| References | |
| Additional Infomation |
2-phosphonobenzoic acid is an aryl phosphate ester.
Fosfosal is a non-acetylated salicylic acid derivative with analgesic and anti-inflammatory activity. It is also known as 2-phosphonoxybenzoic acid. Unlike aspirin, it does not affect prostaglandin biosynthesis in vitro. It is used as a substrate for acid phosphatase estimation. It is an NSAID with a unique mechanism of action. |
| Molecular Formula |
C7H7O6P
|
|---|---|
| Molecular Weight |
218.1
|
| Exact Mass |
217.998
|
| CAS # |
6064-83-1
|
| PubChem CID |
3418
|
| Appearance |
White to off-white solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
482.3±47.0 °C at 760 mmHg
|
| Melting Point |
162-166°C
|
| Flash Point |
245.5±29.3 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.620
|
| LogP |
-0.32
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
14
|
| Complexity |
259
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
P(=O)(O[H])(O[H])OC1=C([H])C([H])=C([H])C([H])=C1C(=O)O[H]
|
| InChi Key |
FFKUDWZICMJVPA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H7O6P/c8-7(9)5-3-1-2-4-6(5)13-14(10,11)12/h1-4H,(H,8,9)(H2,10,11,12)
|
| Chemical Name |
2-phosphonooxybenzoic acid
|
| Synonyms |
Fosfosalum; Disdolen; Fosfosal
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~250 mg/mL (~1146.26 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (229.25 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5851 mL | 22.9253 mL | 45.8505 mL | |
| 5 mM | 0.9170 mL | 4.5851 mL | 9.1701 mL | |
| 10 mM | 0.4585 mL | 2.2925 mL | 4.5851 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
